home / stock / akro / akro articles
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s sess...
Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow tr...
Andrew Cheng, President and CEO at Akero Therapeutics (NASDAQ:AKRO), reported a large exercise of company stock options on October 5, according to ...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing tra...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing tra...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the...